At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 68 enrolled
Drug / intervention
PF-04950615 (RN316) +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
In Brief
A Phase 1 clinical trial evaluating PF-04950615 (RN316) for Hypercholesterolemia and Dyslipidemia. Completed, enrolled 68 participants across 9 sites.
Detailed Summary
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Dyslipidemia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartFeb 2011
Primary CompletionOct 2011
TodayJul 2026
First PostedNov 18, 2010
Enrollment StartFeb 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.6 years ago
Interventions
PF-04950615 (RN316)biological
Infusion every week
PF-04950615 (RN316)biological
Infusion every week
PF-04950615 (RN316)biological
Infusion every week
PF-04950615 (RN316)biological
Infusion every week
PF-04950615 (RN316)biological
Infusion every week